Nav: Home

Emerging therapies show benefit to patients with Crohn's disease and ulcerative colitis

February 07, 2019

Las Vegas, NV (Feb. 7, 2019) -- It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Currently, there are no cures for these diseases.

Studies being presented at the Crohn's & Colitis Congress -- a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, from Feb. 7-9 -- highlight advancements in treatments for patients with IBD.

JAK inhibitors continue to expand their reach in ulcerative colitis

Study Title: The Gut Selective, Orally Administered, PAN-JAK Inhibitor TD-1473 Demonstrates Favorable Safety, Tolerability, Pharmacokinetic, and Signal for Clinical Activity in Subjects with Moderately-to-Severely Active Ulcerative Colitis

W.J Sandborn, University of California San Diego, et al.

Significance: There is a need for effective and safe oral therapeutic options for moderate to severe ulcerative colitis. Oral JAK inhibitors have potential for systemic immunosuppression. PAN-JAK Inhibitor TD-1473 has been designed as a broad inhibitor of the JAK pathway, but with the potential advantage in ulcerative colitis of having a largely topical effect, demonstrating an early signal of efficacy in moderate-to-severe ulcerative colitis.

Biologic therapy targeting immune cell trafficking to the intestine is effective

Significance: IBD patients already benefit from therapy with vedolizumab. Several studies presented at the Crohn's & Colitis Congress highlight other biologics also showing promise for treatment of ulcerative colitis and Crohn's disease.

* Etrolizumab Treatment Modulates Soluable MAdCAM-1 Levels in Serum in Patients with Crohn's Disease
o J. McBride, Genentech Inc., South San Francisco, California, et al.

* Long-term Safety and Efficacy of the Anti-mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-label Extension Study (TURANDOT II)
o W.J. Sandborn, University of California San Diego, et al.

* Long-term Safety, Efficacy and Pharmacokinetics of the Anti-mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Monoclonal Antibody SHP647 in Crohn's Disease: The OPERA II Study
o W.J. Sandborn, University of California San Diego, et al.

All abstracts accepted to the Crohn's & Colitis Congress will be published in Inflammatory Bowel Diseases® (the official journal of the Crohn's & Colitis Foundation) and Gastroenterology (the official journal of the American Gastroenterological Association) on Feb. 7.

Attribution to the Crohn's & Colitis Congress® is requested in all coverage.
-end-
About the Crohn's & Colitis Congress®

The Crohn's & Colitis Congress®, taking place Feb. 7-9, 2019, in Las Vegas, combines the strengths of the nation's leading IBD patient organization, Crohn's & Colitis Foundation, and the premier GI professional association, American Gastroenterological Association (AGA). Together we are committed to convening the greatest minds in IBD to transform patient care. The Crohn's & Colitis Congress is the must-attend meeting for all IBD professionals. Learn more at http://crohnscolitiscongress.org.

About the Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The Foundation's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who are affected by these diseases. The Foundation works to fulfill its mission by funding research; providing educational resources for patients and their families, medical professionals, and the public; and furnishing supportive services for those afflicted with IBD. For more information visit http://www.crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.

About the AGA Institute

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. http://www.gastro.org. Like AGA on Facebook . Follow us on Twitter @AmerGastroAssn. Check out our videos on YouTube. Join AGA on LinkedIn.

American Gastroenterological Association

Related Inflammatory Bowel Disease Articles:

Inflammatory bowel disease: Scientists zoom in on genetic culprits
Scientists have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease.
Social media help identify medication concerns of inflammatory bowel disease patients
Cedars-Sinai researchers analyzed thousands of social media posts to determine the biggest concerns patients with inflammatory bowel disease (IBD) have about their prescribed treatments.
New research suggests new ways to detect and monitor inflammatory bowel disease
A University of Manchester test on the mucus lining of the intestine, performed in mice, has found changes in bacteria that could lead to inflammatory bowel disease 12 weeks earlier than previously possible through looking at stool samples, leading to the possibility of earlier diagnosis and better management of the disease in humans.
Gut microbiome may predict response to biologic therapy for inflammatory bowel disease
Researchers from Massachusetts General Hospital and the Broad Institute of MIT and Harvard have identified differences in the composition and the function of the gut microbiome between patients for whom treatment with a monclonal antibody-based drug was effective in inducing remission of inflammatory bowel disease symptoms and those for whom it was not.
Study identifies a new test to predict severity of inflammatory bowel disease in children
The results from a Norwegian study show that a new genetic test for characterising intestinal microbiota may help to diagnose inflammatory bowel disease (IBD) in children and predict which children will develop the most extensive disease and need early, aggressive intervention.
What's the best way for patients with inflammatory bowel disease to address abdominal pain
When researchers analyzed published studies on how to treat recurrent abdominal pain among patients with inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, stress management appeared to be a promising strategy.
Researchers uncover key role for microRNA in inflammatory bowel disease
An international team of researchers has discovered that a microRNA produced by certain white blood cells can prevent excessive inflammation in the intestine.
Ingesting soy protein may ease severity of inflammatory bowel disease
A diet supplemented with soy protein may be an effective adjunct therapy for inflammatory bowel diseases, Penn State researchers reported after completing a study that included mice and cultured human colon cells.
Study identifies a genetic link to susceptibility and resistance to inflammatory bowel disease
Inflammatory bowel disease (IBD), characterized by chronic relapsing inflammation of the gut, is a common problem in the industrialized world.
Biologic treatments for inflammatory bowel disease help heal the intestine
Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery.

Related Inflammatory Bowel Disease Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".